>Mercado de vectores lentivirales de América del Norte, por componente (promotor lentiviral, etiquetas de fusión lentiviral, sistemas de empaquetado lentiviral, otros), tipo (producto, servicios), generación (cuarta generación, tercera generación, segunda generación, primera generación), flujo de trabajo (procesamiento ascendente, procesamiento descendente), método de administración (in vivo, ex vivo), indicación de enfermedad (cáncer, trastornos genéticos, enfermedades infecciosas, enfermedades veterinarias, otras), aplicación (terapia génica, vacunología), usuario final (empresas de biotecnología, empresas farmacéuticas, organizaciones de investigación por contrato, organización de desarrollo y fabricación por contrato (CDMO), institutos académicos/de investigación), país (EE. UU., Canadá y México) Tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado : mercado de vectores lentivirales en América del Norte
Se espera que el mercado de vectores lentivirales gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 15,8% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 1.156,50 millones para 2028. Se espera que el aumento de la demanda de vectores virales impulse el mercado de vectores lentivirales
Los vectores lentivirales (LV) son vehículos eficientes para la transferencia de genes en células de mamíferos debido a su capacidad de expresar de manera estable un gen de interés en células que no se dividen y en células que se dividen. Los lentivirus son patógenos humanos y animales que se sabe que tienen largos períodos de incubación e infección persistente. El tiempo entre la infección inicial y la aparición de los primeros síntomas puede alcanzar varios meses o años.
Se espera que la aparición de COVID-19 y la demanda de vacunas virales impulsen el mercado de vectores lentivirales. Se espera que la falta de escalabilidad limite el mercado de vectores lentivirales. Se espera que el aumento de la demanda de medicamentos personalizados actúe como una oportunidad para el mercado de vectores lentivirales. Se espera que las estrictas políticas de aprobación del gobierno desafíen el mercado de vectores lentivirales.
El informe de mercado de vectores lentivirales proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de vectores lentivirales, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de vectores lentivirales
The lentiviral vector market is segmented into eight notable segments which are based on the component, type, generation, workflow, delivery method, disease indication, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of component, the lentiviral vector market is segmented into lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems and other. In 2021, lentivirus packaging systems segment is expected to dominate the lentiviral vector market due to growing number of research and development across the globe.
- On the basis of type, the lentiviral vector market is segmented into product and services. In 2021, product segment is expected to dominate the lentiviral vector market due to growing prevalence of infectious diseases.
- On the basis of generation, the lentiviral vector market is segmented into 4th-generation, 3rd-generation, 2nd-generation and 1st-generation. In 2021, 4th-generation segment is expected to dominate the lentiviral vector market due to advanced codon optimization technology being used in vector production with stable integration and high yield formation.
- On the basis of workflow, the lentiviral vector market is segmented into upstream processing and downstream processing. In 2021, upstream processing segment is expected to dominate the lentiviral vector market due to rising investment for research and development activities by major healthcare organizations.
- On the basis of delivery method, the lentiviral vector market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the lentiviral vector market due to its high availability and process reliability.
- On the basis of disease indication, the lentiviral vector market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, cancer segment is expected to dominate the lentiviral vector market owing to the rising incidence and prevalence of genetic disorders.
- On the basis of application, the lentiviral vector market is segmented into gene therapy and vaccinology. In 2021, gene therapy segment is expected to dominate the lentiviral vector market due to broad range of applications in medical sector.
- On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to increasing initiative activities by various healthcare organizations and government bodies to encourage research endeavour.
North America Lentiviral Vector Market Country Level Analysis
North America lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the North America lentiviral vector market report are the U.S., Canada and Mexico.
Upstream processing in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing research advancements in gene therapy. The U.S. is leading the growth of the North America lentiviral vector market and upstream processing segment is dominating in the country because of increasing research and development for the vaccine especially COVID-19 and rising production of therapeutics for the infectious diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Acquisition and Merger is Creating New Opportunities for Players in the Lentiviral Vector Market
The lentiviral vector market also provides you with detailed market analysis for every country growth. Additionally, it provides data regarding acquisition and agreement among the major market plyers and start-up companies. Moreover, growing impact of research and development activities on lentiviral vector market also increases growth pace. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lentiviral Vector Market Share Analysis
The lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to North America lentiviral vector market.
Las principales empresas que participan en el informe del mercado de vectores lentivirales de América del Norte son Applied Biological Materials Inc., Creative Biolabs, bluebird bio, Inc., System Biosciences, LLC, Cobra Biologics Limited, FUJIFILM Diosynth Biotechnologies (una subsidiaria de FUJIFILM Holdings Corporation), Sirion-Biotech GmbH, Merck KGaA, OriGene Technologies, Inc., Sino Biological Inc., Cell Biolabs, Inc., Batavia Biosciences BV, Lonza, Takara Bio Inc., Thermo Fisher Scientific Inc., Waisman Biomanufacturing, Cytiva (una subsidiaria de Danaher), entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de vectores lentivirales.
Por ejemplo,
- En febrero de 2021, Thermo Fisher Scientific Inc. anunció que había ganado seis premios en los premios anuales CMO Leadership Awards. Los premios, otorgados por Life Science Leader y Outsourced Pharma, reconocen a los principales socios de fabricación por contrato según la evaluación de las empresas biofarmacéuticas y biotecnológicas. Se estima que este reconocimiento fortalecerá su presencia a nivel mundial y conducirá a un repunte de su crecimiento en los próximos años.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la presencia de la empresa en el mercado de vectores lentivirales, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LENTIVIRAL VECTOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPONENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW
4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE
4.2.1 PRODUCT
4.2.2 SERVICES
5 NORTH AMERICA LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK
5.1 REGULATION IN THE UNITED STATES
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN DEMAND FOR VIRAL VECTORS
6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES
6.1.5 GROWING GERIATRIC POPULATION
6.2 RESTRAINTS
6.2.1 LACK OF SCALABILITY
6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
6.2.3 SHORTAGE OF SKILLED PERSONNELS
6.3 OPPORTUNITIES
6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS
6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT
6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES
6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION
7 IMPACT OF COVID-19 ON THE NORTH AMERICA LENTIVIRAL VECTOR MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
7.5 CONCLUSION
8 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 LENTIVIRUS PACKAGING SYSTEMS
8.3 LENTIVIRAL PROMOTER
8.3.1 LENTIVIRUS PROMOTER VECTORS
8.3.2 LENTIVIRUS PROMOTERLESS VECTORS
8.4 LENTIVIRAL FUSION TAGS
8.5 OTHERS
9 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRODUCT
9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)
9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)
9.3 SERVICES
10 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY GENERATION
10.1 OVERVIEW
10.2 4TH GENERATION
10.3 3RD GENERATION
10.4 2ND GENERATION
10.5 1ST GENERATION
11 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION & EXPANSION
11.2.2 VECTOR RECOVERY/ HARVESTING
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILL-FINISH
12 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 IN-VIVO
12.3 EX-VIVO
13 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 B-THALESSEMIA
13.3.2 X-LINKED ADRENO LEUKODYSTROPHY
13.3.3 METACHROMATIC LEUKODYSTROPHY
13.3.4 WISKOTT-ALDRICH SYNDROME
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 HIV
13.4.2 OTHERS
13.5 VETERINARY DISEASES
13.6 OTHERS
14 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 GENE THERAPY
14.2.1 RECOMBINANT PROTEIN EXPRESSION
14.2.2 FUNCTIONAL ASSAYS
14.2.3 IN VITRO TRANSCRIPTION
14.2.4 PROTEIN CHARACTERIZATION
14.2.5 OTHERS
14.3 VACCINOLOGY
15 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY END USER
15.1 OVERVIEW
15.2 ACADEMIC/ RESEARCH INSTITUTES
15.3 PHARMACEUTICAL COMPANIES
15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
15.5 BIOTECHNOLOGY COMPANIES
15.6 CONTRACT RESEARCH ORGANIZATIONS
16 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT
19 COMPANY PROFILE
19.1 OXFORD BIOMEDICA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 MERCK KGAA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LONZA
19.4.1 COMPANY SNAPSHOT
19.4.2 RECENT ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 CYTIVA (A SUBSIDIARY OF DANAHER)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 APPLIED BIOLOGICAL MATERIALS INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BATAVIA BIOSCIENCES B.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEBIRD BIO, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 CELL BIOLABS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CREATIVE BIOLABS
19.10.1 COMPANY SNAPSHOT
19.10.2 SERVICE PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 COBRA BIOLOGICS LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 FINVECTOR OY
19.12.1 COMPANY SNAPSHOT
19.12.2 SERVICE PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
19.13.1 COMPANY SNAPSHOT
19.13.2 RECENT ANALYSIS
19.13.3 SERVICE PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 GENEMEDI
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ORIGENE TECHNOLOGIES, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 SINO BIOLOGICAL, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SIRION-BIOTECH GMBH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SYSTEM BIOSCIENCES, LLC
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 TAKARA BIO INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WAISMAN BIOMANUFACTURING
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 THERMO FISHER SCIENTIFIC
TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
TABLE 3 KERAFAST
TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.
TABLE 5 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 U.S. LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 63 U.S. LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 64 U.S. LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 U.S. PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 U.S. LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 67 U.S. LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 68 U.S. UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 69 U.S. DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 70 U.S. LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 71 U.S. LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 72 U.S. GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 73 U.S. INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 74 U.S. LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 U.S. GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 U.S. LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 CANADA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 78 CANADA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 79 CANADA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 CANADA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 CANADA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 82 CANADA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 83 CANADA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 84 CANADA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 85 CANADA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 86 CANADA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 87 CANADA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 88 CANADA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 89 CANADA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 CANADA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 CANADA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 MEXICO LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 93 MEXICO LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 94 MEXICO LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 MEXICO PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 MEXICO LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 97 MEXICO LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 98 MEXICO UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 99 MEXICO DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 100 MEXICO LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 101 MEXICO LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 102 MEXICO GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 103 MEXICO INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 104 MEXICO LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 MEXICO GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 MEXICO LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LENTIVIRAL VECTOR MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LENTIVIRAL VECTOR MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 NORTH AMERICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE NORTH AMERICA LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LENTIVIRAL VECTOR MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LENTIVIRAL VECTOR MARKET
FIGURE 15 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020
FIGURE 16 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2020
FIGURE 20 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020
FIGURE 24 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 27 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020
FIGURE 28 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE
FIGURE 31 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020
FIGURE 32 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 35 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020
FIGURE 36 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 39 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020
FIGURE 40 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 43 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY END USER, 2020
FIGURE 44 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 NORTH AMERICA LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)
FIGURE 52 NORTH AMERICA LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
